Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3...
-
Photo Courtesy of Oakridge Park VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Oakridge Park, Canada’s largest redevelopment, is now open, bringing together global retail, dynamic...
-
PORTOLA VALLEY, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, the nation's leading public charity funder of Lyme disease research, raised $900,000 at LymeAid 2026, its annual...
-
Yamaha Motor Corp., USA, announces the first quarter 2026 grant recipients for its Yamaha Outdoor Access Initiative, with a new logo and website redesign.
-
MENLO PARK, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced that SPRQ-Nx sequencing chemistry and new...
-
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of...
-
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no...
-
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”, HKEX:1801)...
-
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no...
-
10 Companies Selected to Receive Up to $50,000 Each and Accelerate Commercialization of Climate Technologies.